Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues
02:30pm, Wednesday, 07'th Aug 2024
Exelixis (EXEL) beats on earnings and sales in the second quarter. Its shares are trading up in response to the results.
Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
02:15pm, Wednesday, 07'th Aug 2024
In its second-quarter earnings release, Exelixis, Inc. EXEL announced that the final overall survival (OS) analysis for the phase 3 CONTACT-02 trial has been completed.
Exelixis, Inc. (EXEL) Q2 2024 Earnings Call Transcript
09:30pm, Tuesday, 06'th Aug 2024
Exelixis, Inc. (NASDAQ:EXEL ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Mo
Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
07:36pm, Tuesday, 06'th Aug 2024
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare t
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
06:37pm, Tuesday, 06'th Aug 2024
Exelixis (EXEL) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.31 per share a year ago.
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
10:21am, Monday, 05'th Aug 2024
Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Tuesday, 30'th Jul 2024
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
04:05pm, Tuesday, 23'rd Jul 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5
7 Cheap Biotech Stocks With Major Upside Potential
06:00am, Tuesday, 09'th Jul 2024
Intuitively, the case for biotechnology-related investments comes across rather obviously: the concept of healthcare should be a permanent one. And because of this permanence, the expected market valu
Insider Buying Heats Up at Fracker, Aircraft and Boat Makers, and More
09:15am, Sunday, 02'nd Jun 2024
With the earnings-reporting season having all but concluded, the windows for making insider purchases are generally open.
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
04:05pm, Tuesday, 28'th May 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the William Blair 44th Annual Growth Stock Conference on
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
12:21pm, Tuesday, 21'st May 2024
Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
08:00am, Monday, 20'th May 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectivel
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
01:25pm, Sunday, 12'th May 2024
Novo Nordisk and Exelixis are favorites of billionaire Jim Simons' hedge fund. Novo Nordisk has a deep lineup and pipeline and expertise in diabetes and obesity.
Just Say No to Drugs: 3 Pharma Stocks to Avoid
10:30am, Wednesday, 08'th May 2024
From its stellar performance in 2021 to deflating in 2022, the biotech sector continued its stagnation into 2023, highlighting some pharma stocks to avoid. Year-to-date, the S&P Biotechnology Select I
